Conflict of interest declaration: Tom Jefferson

Roles in: Acute Respiratory Infections Group

1. In the past three years have you accepted the following from an organisation that may gain or lose financially from the publication of reviews by your review group in the Cochrane Database of Systematic Reviews (CDSR)?

a) Reimbursement for attending a conference or symposium (including travel, accommodation and/or hospitality)?
No

b) Fees for speaking?
No

c) Fees for organising education?
No

d) Funds for research?
Yes - This is a general statement giving details over and beyond the required time span: TJ was a recipient of a UK National Institute for Health Research grant for a Cochrane review of neuraminidase inhibitors for influenza. In addition, TJ receives royalties from his books published by Il Pensiero Scientifico Editore, Rome and Blackwells. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011-13, TJ acted as an expert witness in litigation related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage (including the vaccine Pandemrix (2015-2017) and in a labour case on influenza vaccines in healthcare workers in Canada. He has acted as a consultant for Roche (1997-99), GSK (2001-2), Sanofi-Synthelabo (2003), and IMS Health (2013).In 2014 he was retained as a scientific adviser to a legal team acting on oseltamivir. TJ has a potential financial conflict of interest in the drug oseltamivir. In 2014-16, TJ was a member of three advisory boards for Boerhinger Ingelheim. TJ was holder of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. Between 1994 and 2013, TJ was the coordinator of the Cochrane Vaccines Field. TJ was a co-signatory of the Nordic Cochrane Centre Complaint to the European Medicines Agency (EMA) over maladministration at the EMA in relation to the investigation of alleged harms of HPV vaccines and consequent complaints to the European Ombudsman. TJ is co-holder of a John and Laura Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

e) Funds for a member of staff?
No

f) Fees for consulting?
Yes - See above

g) Royalty payments?
Yes - See above

2. In the past three years have you or your spouse/partner been employed by an organization that may in any way gain or lose financially from the publication of reviews by your review group in the CDSR?
No

3. Do you own stocks or shares in companies that may gain or lose financially from the publication of reviews by your review group in the CDSR?
No

4. Do you hold any patents for products that that may lead you to gain or lose financially from the publication of reviews by your review group in the CDSR?
No

5. Do you have any other competing interests (financial or non-financial)?
Yes - See above